Navigation Links
eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
Date:2/11/2008

PHILADELPHIA, Feb. 11 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services including expert consultation and a provider of eClinical technology and services (electronic data capture and electronic patient reported outcomes solutions), announced today that it will release its 2007 fourth quarter results for the period ended December 31, 2007 on Tuesday, February 26, 2008 after the market closes. After the release, the Company will host a conference call at 5:00 PM ET later that day.

For the conference call interested participants should dial 866-578-5771 when calling within the United States or 617-213-8055 when calling internationally. Please use pass code 91743845. There will be a playback available as well. To listen to the playback, please call 888-286-8010 when calling within the United States or 617-801-6888 when calling internationally. Please use pass code 46120621 for the replay.

This call is being webcast by Thomson Financial and can be accessed at eRT's web site at http://www.eRT.com. The webcast may also be accessed at Thomson's Institutional Investor website at http://phx.corporate-ir.net/playerlink.zhtml?c=119164&s=wm&e=1764127 . The webcast can be accessed until February 26, 2009 on either site.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
2. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
3. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
4. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
5. Genta Announces Common Stock Offering of Approximately $3.1 Million
6. Chakshu Research Announces Appointment of Dr. Randall Olson as Director
7. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
8. onTargetjobs Announces Acquisition of RegionalHelpWanted.com
9. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
10. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
11. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Newly formed Advisory Board to advise on cancer screening ... mitochondrial DNA-based ... Inc. (OTC,Bulletin Board: TBIO) today announced that it has ... the latest developments and,scientific opportunities in cancer detection screening ...
... ... Use, LA JOLLA, Calif., Jan. 17 Stemagen, a privately ... in the world to create, and meticulously document, a cloned human,embryo ... Wood, M.D., Ph.D., a co-author of the,publication and a donor of ...
... Trial will also Support a Marketing Authorization Application in the ... ... Agennix Incorporated announced today,that the U.S. Food and Drug Administration ... evaluating its lead molecule,talactoferrin alfa, in combination with chemotherapy as first-line,treatment ...
Cached Biology Technology:Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Ancient DNA offers clues to how barnyard chickens came to be 2Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... form of skin cancer, can be successfully treated in some ... work and why they are only effective in some patients ... articles in the January 17 issue of the Journal of ... of immune cells called killer T cells that can attack ...
... with high-risk breast cancer treated with radical mastectomy and ... better survival outcomes with few long-term toxic effects, according ... appears in the January 19 issue of the Journal ... randomized radiation therapy trial was designed to determine the ...
... results of a recent U.S. study, investigators in Japan ... potentially life-threatening form of high blood pressure, as reported ... Infectious Diseases, now available online. , The researchers reported ... 8 (HHV-8), also known as the Kaposi's sarcoma virus, ...
Cached Biology News:Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer 2Association of herpesvirus with lung disorder questioned 2
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
... Series 4000 incorporates the critical design features ... in biomarker research. The Series 4000 delivers ... converting biomarker discoveries to biomarker assays all ... is designed to fit into the research ...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
Biology Products: